Nanoscope Therapeutics to Present at the 2024 American Society of Retina Specialists (ASRS) Annual Scientific Meeting
10 Jul 2024
DALLAS, July 10, 2024 /PRNewswire/ -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD)AMD), today announced that its Multi-Characteristic Opsin (MCO) gene therapy platform will be featured in a presentation by Dr. Michael Singer, Clinical Professor of Ophthalmology at the University of Texas Health Science Center, at the 2024 ASRS Annual Scientific Meeting taking place from July 17-July 20, 2024 at the Stockholmsmässan Convention Center in Stockholm, Sweden.
Details for the presentation are as follows:
Abstract Title: BCVA analysis of low- or high-dose MCO-010 mutation agnostic optogenetic therapy for retinitis pigmentosa: FIRST TIME 100-week TOPLINE Results from a Phase 2b/3 Randomized Sham-Controlled Clinical Trial (RESTORE)
Session Type: Late-Breaking Symposium Presentation
Session Title: Symposium 3: Hereditary Retinal Disease & Genetics
Session Date: Friday, July 19th
Session Time: 9:17am CEST
Presenter: Dr. Michael Singer, Clinical Professor of Ophthalmology at the University of Texas Health Science Center
Dr. Singer will present end-of-study data from RESTORE, a randomized controlled trial of Nanoscope's MCO optogenetic gene therapy in patients with severe vision loss related to Retinitis Pigmentosa (RP). MCO-treated subjects from RESTORE experienced clinically meaningful improvements in best-corrected visual acuity (BCVA) in a statistically significant manner. Dr. Singer will discuss the importance and magnitude of the vision restoration observed in MCO-treated patients from RESTORE in the context of the natural history of declining vision in this patient population.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by inherited retinal diseases, for which no cure exists. The company's lead asset, MCO-010, recently announced the 100-week data from the RESTORE Phase 2b/3 multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772). The company has also recently completed the Phase 2 STARLIGHT trial of MCO-010 therapy in patients with Stargardt disease (NCT05417126 ). MCO-010 has received FDA fast-track designations and FDA orphan drug designations for both retinitis pigmentosa and Stargardt disease. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophies secondary to AMDAMD.
Investor Contact:
Argot Partners
212-600-1902
[email protected]
SOURCE Nanoscope Therapeutics
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.